Treatment satisfaction and glycemic control in young Type 1 diabetic patients in transition from pediatric health care: CSII versus MDI
To evaluate whether continuous subcutaneous insulin infusion (CSII) may have any advantage over multiple daily injections (MDI) on glycemic control and treatment satisfaction in young patients with Type 1 diabetes in transition to an adult diabetes center. The study population consisted of 125 patie...
Gespeichert in:
| Veröffentlicht in: | Endocrine 2014-06, Vol.46 (2), p.256-262 |
|---|---|
| Hauptverfasser: | , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 262 |
|---|---|
| container_issue | 2 |
| container_start_page | 256 |
| container_title | Endocrine |
| container_volume | 46 |
| creator | Maiorino, Maria Ida Bellastella, Giuseppe Petrizzo, Michela Improta, Maria Rosaria Brancario, Clementina Castaldo, Filomena Olita, Laura Giugliano, Dario Esposito, Katherine |
| description | To evaluate whether continuous subcutaneous insulin infusion (CSII) may have any advantage over multiple daily injections (MDI) on glycemic control and treatment satisfaction in young patients with Type 1 diabetes in transition to an adult diabetes center. The study population consisted of 125 patients on MDI; 38 out of the 43 patients considered eligible for CSII completed the study and the 82 remaining on MDI served as control group. Glycemic control and treatment satisfaction [diabetes treatment satisfaction questionnaire (DTSQ)] were evaluated in all patients at baseline and after 12 weeks. At baseline, the two groups were well matched for demographic characteristics and glycemic control. DTSQ score was lower in CSII group (21.1 ± 8.8 vs. 25.1 ± 7.1,
P
= 0.011). After 12 weeks, a similar decrease in HbA1C was observed in both groups [difference −0.3 % (95 % CI −0.6 to 0.1,
P
= 0.847)]. Mean amplitude glucose excursions, blood glucose standard deviation, and overall hypoglycemia were significantly reduced in CSII group. DTSQ overall score increased in CSII and decreased in MDI (difference between groups = 9.9, 95 % CI 8.0–12.0,
P
|
| doi_str_mv | 10.1007/s12020-013-0060-6 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_1543995317</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>1543995317</sourcerecordid><originalsourceid>FETCH-LOGICAL-c344t-23f98934d9b083e950c64a927c938548f278b032165c57109215b6224da2af913</originalsourceid><addsrcrecordid>eNp9kMtu1DAUhi0Eohd4ADbISzaB41sSs0PDpSMVddFBYmc5zsk0VWIH20GaJ-C18TCly66Odc73f5J_Qt4weM8Amg-JceBQARMVQA1V_YycM6V02QA8L2-hVLm0P8_IRUr3AJzzunlJzriEppUMzsmfXUSbZ_SZJpvHNFiXx-Cp9T3dTweH8-ioCz7HMNHR00NY_Z7uDgtSRvvRdpgLsJRoUaQjkaP1afwnGWKY6YIFy7FQd2infEedjfiRbm63W_obY1oT_f55-4q8GOyU8PXDvCQ_vn7Zba6q65tv282n68oJKXPFxaBbLWSvO2gFagWullbzxmnRKtkOvGk7EJzVyqmGgeZMdTXnsrfcDpqJS_Lu5F1i-LViymYek8Npsh7DmgxTUmitBGsKyk6oiyGliINZ4jjbeDAMzLF_c-rflP7NsX9Tl8zbB_3azdg_Jv4XXgB-AlI5-T1Gcx_W6MuXn7D-BR8sj9c</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>1543995317</pqid></control><display><type>article</type><title>Treatment satisfaction and glycemic control in young Type 1 diabetic patients in transition from pediatric health care: CSII versus MDI</title><source>MEDLINE</source><source>SpringerLink Journals - AutoHoldings</source><creator>Maiorino, Maria Ida ; Bellastella, Giuseppe ; Petrizzo, Michela ; Improta, Maria Rosaria ; Brancario, Clementina ; Castaldo, Filomena ; Olita, Laura ; Giugliano, Dario ; Esposito, Katherine</creator><creatorcontrib>Maiorino, Maria Ida ; Bellastella, Giuseppe ; Petrizzo, Michela ; Improta, Maria Rosaria ; Brancario, Clementina ; Castaldo, Filomena ; Olita, Laura ; Giugliano, Dario ; Esposito, Katherine</creatorcontrib><description>To evaluate whether continuous subcutaneous insulin infusion (CSII) may have any advantage over multiple daily injections (MDI) on glycemic control and treatment satisfaction in young patients with Type 1 diabetes in transition to an adult diabetes center. The study population consisted of 125 patients on MDI; 38 out of the 43 patients considered eligible for CSII completed the study and the 82 remaining on MDI served as control group. Glycemic control and treatment satisfaction [diabetes treatment satisfaction questionnaire (DTSQ)] were evaluated in all patients at baseline and after 12 weeks. At baseline, the two groups were well matched for demographic characteristics and glycemic control. DTSQ score was lower in CSII group (21.1 ± 8.8 vs. 25.1 ± 7.1,
P
= 0.011). After 12 weeks, a similar decrease in HbA1C was observed in both groups [difference −0.3 % (95 % CI −0.6 to 0.1,
P
= 0.847)]. Mean amplitude glucose excursions, blood glucose standard deviation, and overall hypoglycemia were significantly reduced in CSII group. DTSQ overall score increased in CSII and decreased in MDI (difference between groups = 9.9, 95 % CI 8.0–12.0,
P
< 0.001), while perceived hyperglycemia and hypoglycemia decreased in CSII compared with MDI (difference: −2.5 and −2.0, respectively,
P
< 0.001 for both). Among young Type 1 diabetic patients in transition from Pediatrics, CSII showed a similar efficacy in reducing HbA1c compared with MDI, with less hypoglycemia and glycemic excursions, and was better in improving overall treatment satisfaction and the rate of perceived hyperglycemia and hypoglycemia.</description><identifier>ISSN: 1355-008X</identifier><identifier>EISSN: 1559-0100</identifier><identifier>DOI: 10.1007/s12020-013-0060-6</identifier><identifier>PMID: 24078410</identifier><language>eng</language><publisher>Boston: Springer US</publisher><subject>Adolescent ; Adult ; Blood Glucose ; Diabetes ; Diabetes Mellitus, Type 1 - drug therapy ; Drug Administration Schedule ; Endocrinology ; Female ; Glycated Hemoglobin A ; Humanities and Social Sciences ; Humans ; Hypoglycemic Agents - therapeutic use ; Insulin - therapeutic use ; Insulin Infusion Systems ; Internal Medicine ; Male ; Medicine ; Medicine & Public Health ; multidisciplinary ; Original Article ; Patient Satisfaction ; Science ; Surveys and Questionnaires ; Transition to Adult Care ; Young Adult</subject><ispartof>Endocrine, 2014-06, Vol.46 (2), p.256-262</ispartof><rights>Springer Science+Business Media New York 2013</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c344t-23f98934d9b083e950c64a927c938548f278b032165c57109215b6224da2af913</citedby><cites>FETCH-LOGICAL-c344t-23f98934d9b083e950c64a927c938548f278b032165c57109215b6224da2af913</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://link.springer.com/content/pdf/10.1007/s12020-013-0060-6$$EPDF$$P50$$Gspringer$$H</linktopdf><linktohtml>$$Uhttps://link.springer.com/10.1007/s12020-013-0060-6$$EHTML$$P50$$Gspringer$$H</linktohtml><link.rule.ids>314,780,784,27924,27925,41488,42557,51319</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/24078410$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Maiorino, Maria Ida</creatorcontrib><creatorcontrib>Bellastella, Giuseppe</creatorcontrib><creatorcontrib>Petrizzo, Michela</creatorcontrib><creatorcontrib>Improta, Maria Rosaria</creatorcontrib><creatorcontrib>Brancario, Clementina</creatorcontrib><creatorcontrib>Castaldo, Filomena</creatorcontrib><creatorcontrib>Olita, Laura</creatorcontrib><creatorcontrib>Giugliano, Dario</creatorcontrib><creatorcontrib>Esposito, Katherine</creatorcontrib><title>Treatment satisfaction and glycemic control in young Type 1 diabetic patients in transition from pediatric health care: CSII versus MDI</title><title>Endocrine</title><addtitle>Endocrine</addtitle><addtitle>Endocrine</addtitle><description>To evaluate whether continuous subcutaneous insulin infusion (CSII) may have any advantage over multiple daily injections (MDI) on glycemic control and treatment satisfaction in young patients with Type 1 diabetes in transition to an adult diabetes center. The study population consisted of 125 patients on MDI; 38 out of the 43 patients considered eligible for CSII completed the study and the 82 remaining on MDI served as control group. Glycemic control and treatment satisfaction [diabetes treatment satisfaction questionnaire (DTSQ)] were evaluated in all patients at baseline and after 12 weeks. At baseline, the two groups were well matched for demographic characteristics and glycemic control. DTSQ score was lower in CSII group (21.1 ± 8.8 vs. 25.1 ± 7.1,
P
= 0.011). After 12 weeks, a similar decrease in HbA1C was observed in both groups [difference −0.3 % (95 % CI −0.6 to 0.1,
P
= 0.847)]. Mean amplitude glucose excursions, blood glucose standard deviation, and overall hypoglycemia were significantly reduced in CSII group. DTSQ overall score increased in CSII and decreased in MDI (difference between groups = 9.9, 95 % CI 8.0–12.0,
P
< 0.001), while perceived hyperglycemia and hypoglycemia decreased in CSII compared with MDI (difference: −2.5 and −2.0, respectively,
P
< 0.001 for both). Among young Type 1 diabetic patients in transition from Pediatrics, CSII showed a similar efficacy in reducing HbA1c compared with MDI, with less hypoglycemia and glycemic excursions, and was better in improving overall treatment satisfaction and the rate of perceived hyperglycemia and hypoglycemia.</description><subject>Adolescent</subject><subject>Adult</subject><subject>Blood Glucose</subject><subject>Diabetes</subject><subject>Diabetes Mellitus, Type 1 - drug therapy</subject><subject>Drug Administration Schedule</subject><subject>Endocrinology</subject><subject>Female</subject><subject>Glycated Hemoglobin A</subject><subject>Humanities and Social Sciences</subject><subject>Humans</subject><subject>Hypoglycemic Agents - therapeutic use</subject><subject>Insulin - therapeutic use</subject><subject>Insulin Infusion Systems</subject><subject>Internal Medicine</subject><subject>Male</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>multidisciplinary</subject><subject>Original Article</subject><subject>Patient Satisfaction</subject><subject>Science</subject><subject>Surveys and Questionnaires</subject><subject>Transition to Adult Care</subject><subject>Young Adult</subject><issn>1355-008X</issn><issn>1559-0100</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2014</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtu1DAUhi0Eohd4ADbISzaB41sSs0PDpSMVddFBYmc5zsk0VWIH20GaJ-C18TCly66Odc73f5J_Qt4weM8Amg-JceBQARMVQA1V_YycM6V02QA8L2-hVLm0P8_IRUr3AJzzunlJzriEppUMzsmfXUSbZ_SZJpvHNFiXx-Cp9T3dTweH8-ioCz7HMNHR00NY_Z7uDgtSRvvRdpgLsJRoUaQjkaP1afwnGWKY6YIFy7FQd2infEedjfiRbm63W_obY1oT_f55-4q8GOyU8PXDvCQ_vn7Zba6q65tv282n68oJKXPFxaBbLWSvO2gFagWullbzxmnRKtkOvGk7EJzVyqmGgeZMdTXnsrfcDpqJS_Lu5F1i-LViymYek8Npsh7DmgxTUmitBGsKyk6oiyGliINZ4jjbeDAMzLF_c-rflP7NsX9Tl8zbB_3azdg_Jv4XXgB-AlI5-T1Gcx_W6MuXn7D-BR8sj9c</recordid><startdate>20140601</startdate><enddate>20140601</enddate><creator>Maiorino, Maria Ida</creator><creator>Bellastella, Giuseppe</creator><creator>Petrizzo, Michela</creator><creator>Improta, Maria Rosaria</creator><creator>Brancario, Clementina</creator><creator>Castaldo, Filomena</creator><creator>Olita, Laura</creator><creator>Giugliano, Dario</creator><creator>Esposito, Katherine</creator><general>Springer US</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope></search><sort><creationdate>20140601</creationdate><title>Treatment satisfaction and glycemic control in young Type 1 diabetic patients in transition from pediatric health care: CSII versus MDI</title><author>Maiorino, Maria Ida ; Bellastella, Giuseppe ; Petrizzo, Michela ; Improta, Maria Rosaria ; Brancario, Clementina ; Castaldo, Filomena ; Olita, Laura ; Giugliano, Dario ; Esposito, Katherine</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c344t-23f98934d9b083e950c64a927c938548f278b032165c57109215b6224da2af913</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2014</creationdate><topic>Adolescent</topic><topic>Adult</topic><topic>Blood Glucose</topic><topic>Diabetes</topic><topic>Diabetes Mellitus, Type 1 - drug therapy</topic><topic>Drug Administration Schedule</topic><topic>Endocrinology</topic><topic>Female</topic><topic>Glycated Hemoglobin A</topic><topic>Humanities and Social Sciences</topic><topic>Humans</topic><topic>Hypoglycemic Agents - therapeutic use</topic><topic>Insulin - therapeutic use</topic><topic>Insulin Infusion Systems</topic><topic>Internal Medicine</topic><topic>Male</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>multidisciplinary</topic><topic>Original Article</topic><topic>Patient Satisfaction</topic><topic>Science</topic><topic>Surveys and Questionnaires</topic><topic>Transition to Adult Care</topic><topic>Young Adult</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Maiorino, Maria Ida</creatorcontrib><creatorcontrib>Bellastella, Giuseppe</creatorcontrib><creatorcontrib>Petrizzo, Michela</creatorcontrib><creatorcontrib>Improta, Maria Rosaria</creatorcontrib><creatorcontrib>Brancario, Clementina</creatorcontrib><creatorcontrib>Castaldo, Filomena</creatorcontrib><creatorcontrib>Olita, Laura</creatorcontrib><creatorcontrib>Giugliano, Dario</creatorcontrib><creatorcontrib>Esposito, Katherine</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Endocrine</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Maiorino, Maria Ida</au><au>Bellastella, Giuseppe</au><au>Petrizzo, Michela</au><au>Improta, Maria Rosaria</au><au>Brancario, Clementina</au><au>Castaldo, Filomena</au><au>Olita, Laura</au><au>Giugliano, Dario</au><au>Esposito, Katherine</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Treatment satisfaction and glycemic control in young Type 1 diabetic patients in transition from pediatric health care: CSII versus MDI</atitle><jtitle>Endocrine</jtitle><stitle>Endocrine</stitle><addtitle>Endocrine</addtitle><date>2014-06-01</date><risdate>2014</risdate><volume>46</volume><issue>2</issue><spage>256</spage><epage>262</epage><pages>256-262</pages><issn>1355-008X</issn><eissn>1559-0100</eissn><abstract>To evaluate whether continuous subcutaneous insulin infusion (CSII) may have any advantage over multiple daily injections (MDI) on glycemic control and treatment satisfaction in young patients with Type 1 diabetes in transition to an adult diabetes center. The study population consisted of 125 patients on MDI; 38 out of the 43 patients considered eligible for CSII completed the study and the 82 remaining on MDI served as control group. Glycemic control and treatment satisfaction [diabetes treatment satisfaction questionnaire (DTSQ)] were evaluated in all patients at baseline and after 12 weeks. At baseline, the two groups were well matched for demographic characteristics and glycemic control. DTSQ score was lower in CSII group (21.1 ± 8.8 vs. 25.1 ± 7.1,
P
= 0.011). After 12 weeks, a similar decrease in HbA1C was observed in both groups [difference −0.3 % (95 % CI −0.6 to 0.1,
P
= 0.847)]. Mean amplitude glucose excursions, blood glucose standard deviation, and overall hypoglycemia were significantly reduced in CSII group. DTSQ overall score increased in CSII and decreased in MDI (difference between groups = 9.9, 95 % CI 8.0–12.0,
P
< 0.001), while perceived hyperglycemia and hypoglycemia decreased in CSII compared with MDI (difference: −2.5 and −2.0, respectively,
P
< 0.001 for both). Among young Type 1 diabetic patients in transition from Pediatrics, CSII showed a similar efficacy in reducing HbA1c compared with MDI, with less hypoglycemia and glycemic excursions, and was better in improving overall treatment satisfaction and the rate of perceived hyperglycemia and hypoglycemia.</abstract><cop>Boston</cop><pub>Springer US</pub><pmid>24078410</pmid><doi>10.1007/s12020-013-0060-6</doi><tpages>7</tpages></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1355-008X |
| ispartof | Endocrine, 2014-06, Vol.46 (2), p.256-262 |
| issn | 1355-008X 1559-0100 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_1543995317 |
| source | MEDLINE; SpringerLink Journals - AutoHoldings |
| subjects | Adolescent Adult Blood Glucose Diabetes Diabetes Mellitus, Type 1 - drug therapy Drug Administration Schedule Endocrinology Female Glycated Hemoglobin A Humanities and Social Sciences Humans Hypoglycemic Agents - therapeutic use Insulin - therapeutic use Insulin Infusion Systems Internal Medicine Male Medicine Medicine & Public Health multidisciplinary Original Article Patient Satisfaction Science Surveys and Questionnaires Transition to Adult Care Young Adult |
| title | Treatment satisfaction and glycemic control in young Type 1 diabetic patients in transition from pediatric health care: CSII versus MDI |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-04T16%3A58%3A07IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Treatment%20satisfaction%20and%20glycemic%20control%20in%20young%20Type%201%20diabetic%20patients%20in%20transition%20from%20pediatric%20health%20care:%20CSII%20versus%20MDI&rft.jtitle=Endocrine&rft.au=Maiorino,%20Maria%20Ida&rft.date=2014-06-01&rft.volume=46&rft.issue=2&rft.spage=256&rft.epage=262&rft.pages=256-262&rft.issn=1355-008X&rft.eissn=1559-0100&rft_id=info:doi/10.1007/s12020-013-0060-6&rft_dat=%3Cproquest_cross%3E1543995317%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=1543995317&rft_id=info:pmid/24078410&rfr_iscdi=true |